ライフサイエンスコーパス: dipivoxil

1 multinational phase III studies of adefovir dipivoxil.

2 greater potency than lamivudine and adefovir dipivoxil.

3 mprenavir, abacavir, efavirenz, and adefovir dipivoxil.

4 , followed by 6 weeks of open-label adefovir dipivoxil.

5 ment in the liver/kidney ratio over adefovir dipivoxil.

6 ine-resistant HBV were treated with adefovir dipivoxil 10 mg once daily.

7 with lamivudine were randomized to adefovir dipivoxil 10 mg, lamivudine 100 mg, or addition of adefo

8 Forty-eight weeks of adefovir dipivoxil 10-mg therapy resulted in potent reductions in

9 Antiviral efficacy of adefovir dipivoxil 10-mg therapy was examined with respect to HBV

10 y 1 of the 24 subjects who received adefovir dipivoxil (125 mg/day) developed any genotypic change fr

11 Adefovir dipivoxil [9-(2-(bispivaloyloxymethyl)phosphonylmethoxye

12 We have found that adefovir dipivoxil, a drug approved to treat chronic infection of

13 Adefovir dipivoxil, a marketed drug for the treatment of hepatiti

14 Adefovir dipivoxil, a prototype phosphonate analog, has been appr

15 weeks of TDF 300 mg (HVL n = 82) or adefovir dipivoxil (ADV) 10 mg (HVL n = 47), followed by open-lab

16 fovir disoproxil fumarate (TDF) and adefovir dipivoxil (ADV) are licensed for the treatment of HIV-1

17 Adefovir dipivoxil (ADV) has demonstrated clinical activity again

18 cy, safety, and pharmacokinetics of adefovir dipivoxil (ADV) in children and adolescents with chronic

19 -term (4 or 5 years) treatment with adefovir dipivoxil (ADV).

20 ility to, and treatment failure of, adefovir dipivoxil (ADV).

21 n reported in patients treated with adefovir dipivoxil (ADV); however, its incidence and clinical imp

22 zed 2:1 to receive TDF (n = 426) or adefovir dipivoxil (ADV; n = 215) for 48 weeks.

23 assessed the safety and efficacy of adefovir dipivoxil alone and in combination with lamivudine compa

24 nsated liver disease, indicate that adefovir dipivoxil alone or in combination with ongoing lamivudin

25 ontrolled, dose-escalation study of adefovir dipivoxil, an oral prodrug of adefovir, was conducted in

26 This study provides evidence that adefovir dipivoxil can be an effective treatment for lamivudine-r

27 placebo or one of three dosages of adefovir dipivoxil daily for 14 days.

28 een by 4 weeks in all recipients of adefovir dipivoxil; DAVG(16) was -0.07 in the lamivudine group co

29 After 14 days of dosing, adefovir dipivoxil demonstrated anti-HIV activity and was best to

30 d in a phase I/II clinical trial of adefovir dipivoxil demonstrated that the K70E RT mutation develop

31 d patients treated daily with 30 mg adefovir dipivoxil for 12 weeks displayed a median 4.1-log10 decr

32 ents who entered clinical trials of adefovir dipivoxil for the treatment of lamivudine-resistant HBV.

33 adefovir dipivoxil/lamivudine, and adefovir dipivoxil groups, respectively.

34 Adefovir dipivoxil has a superior first line resistance profile a

35 The patients were treated with adefovir dipivoxil in a dose of 5 to 30 mg daily.

36 ted adverse effects associated with adefovir dipivoxil in this setting were primarily mild to moderat

37 , the active cellular metabolite of adefovir dipivoxil, inhibits the adenylyl cyclase activity of EF

38 Adefovir dipivoxil is a clinically approved drug that can block t

39 Adefovir dipivoxil is a novel nucleotide analogue with several pr

40 Adefovir dipivoxil is a nucleotide analog that has demonstrated e

41 Adefovir dipivoxil is a promising new treatment for lamivudine-re

42 evaluated once-daily treatment with adefovir dipivoxil, lamivudine, didanosine, and efavirenz.

43 and -2.46 log(10) copies/mL in the adefovir dipivoxil/lamivudine and adefovir dipivoxil monotherapy

44 3%) and 9 of 18 (47%) recipients of adefovir dipivoxil/lamivudine and adefovir dipivoxil, respectivel

45 nts receiving adefovir dipivoxil or adefovir dipivoxil/lamivudine and none receiving lamivudine monot

46 og(10) copies/mL in the lamivudine, adefovir dipivoxil/lamivudine, and adefovir dipivoxil groups, res

47 e adefovir dipivoxil/lamivudine and adefovir dipivoxil monotherapy groups, respectively (P < 0.001).

48 evaluate the safety and efficacy of adefovir dipivoxil monotherapy, a randomized, double-blind, place

49 ve either a single 120-mg/d dose of adefovir dipivoxil (n = 219) or an indistinguishable placebo (n =

50 Three patients receiving adefovir dipivoxil or adefovir dipivoxil/lamivudine and none rece

51 assigned in a 2:1 ratio to receive adefovir dipivoxil or placebo as a once-daily oral dose for 6 wee

52 Adefovir dipivoxil possesses potent in vitro and in vivo antivira

53 f adefovir dipivoxil/lamivudine and adefovir dipivoxil, respectively, compared with 1 of 19 (5%) reci

54 In conclusion, 48 weeks of adefovir dipivoxil resulted in significant improvements in virolo

55 els were significantly greater with adefovir dipivoxil than with placebo.

56 Forty-eight weeks of adefovir dipivoxil therapy resulted in significant decreases in s

57 se (RT) potentially attributable to adefovir dipivoxil therapy.

58 sistance mutations may benefit from adefovir dipivoxil therapy.

59 d the efficacy and safety of adding adefovir dipivoxil to lamivudine in 135 patients with chronic hep

60 The addition of adefovir dipivoxil to lamivudine in patients with CHB with compen

61 , lamivudine 100 mg, or addition of adefovir dipivoxil to ongoing lamivudine daily.

62 a phase II study of 6-12 months of adefovir dipivoxil treatment in human immunodeficiency virus (HIV

63 Adefovir dipivoxil was determined to be safe and well-tolerated w

64 Adefovir dipivoxil was safe and effective for treatment-naive pat

65 Hepatitis B immunoglobulin and adefovir dipivoxil were initiated.